Fluticasone furoate/vilanterol prescribing across the NHS.
Fluticasone furoate with vilanterol is the once-daily ICS/LABA, 883,000 items a year, and it is shrinking as its own manufacturer's triple therapy absorbs the COPD end of its market. A product being cannibalised by its successor is a familiar shape in this dataset.
The NHS in England dispensed 867,569 prescription items of Fluticasone furoate/vilanterol in the 12 months to May 2026, across primary care and hospitals.
Spending on Fluticasone furoate/vilanterol over those 12 months was £25.1m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were down 13.0% on the previous 12 months.
100% of Fluticasone furoate/vilanterol volume moved through primary care and 0% through hospital pharmacies.
Fluticasone furoate/vilanterol ranks #7 of 11 chemical substances in Corticosteroids (respiratory) (BNF 3.2), by items dispensed.
Among Integrated Care Boards, NHS Greater Manchester ICB dispensed the highest volume of Fluticasone furoate/vilanterol.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
| Month | Items | Spend (NIC) |
|---|---|---|
| May 2026 | 64,937 | £1.9m |
| April 2026 | 67,456 | £2.0m |
| March 2026 | 69,779 | £2.0m |
| February 2026 | 64,786 | £1.9m |
| January 2026 | 72,358 | £2.1m |
| December 2025 | 76,383 | £2.2m |
| November 2025 | 69,892 | £2.0m |
| October 2025 | 77,187 | £2.2m |
| September 2025 | 75,764 | £2.2m |
| August 2025 | 72,426 | £2.1m |
| July 2025 | 79,850 | £2.3m |
| June 2025 | 76,751 | £2.2m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
3.0% of its class.
Fluticasone furoate/vilanterol ranks #7 of 11 chemical substances in Corticosteroids (respiratory) (BNF 3.2), by items dispensed in May 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
Fluticasone furoate/vilanterol across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much fluticasone furoate/vilanterol its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Fluticasone furoate/vilanterol is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS Greater Manchester ICB 90k
- 2 NHS West Yorkshire ICB 71k
- 3 NHS Cheshire and Merseyside ICB 60k
- – + 33 more. Unlock the full 36-ICB table. Unlock →
- 1 NHS Leicester, Leicestershire and Rutland ICB +9.1%
- 2 NHS Northamptonshire ICB +3.7%
- 3 NHS Derby and Derbyshire ICB -3.8%
- – + 33 more. Unlock every ICB, ranked. Unlock →
- 1 Relvar Ellipta 92microg/dose / 22microg/dose dry pdr inh 61%
- 2 Relvar Ellipta 184microg/dose / 22microg/dose dry pdr inh 35%
- 3 Fluticasone furoate 92microg/Vilanterol 22microg/dose 2%
- – + 1 more. Unlock every strength and pack. Unlock →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 868k | May 2026 |
| Northern Ireland | 78k | May 2026 |
| Scotland | 230k | April 2026 |
| Wales | 175k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland.
What open data won't tell you about fluticasone furoate/vilanterol.
Asthma and COPD use are indistinguishable here, and the cannibalisation reading is inference from adjacent lines, not recorded fact.
Asked and answered.
Is fluticasone furoate/vilanterol prescribing rising or falling in the NHS?
Falling. England dispensed 867,569 items of Fluticasone furoate/vilanterol in the 12 months to May 2026, down 13.0% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on fluticasone furoate/vilanterol?
£25.1m at net ingredient cost in the 12 months to May 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is fluticasone furoate/vilanterol prescribed most?
By raw volume, NHS Greater Manchester ICB dispensed the most fluticasone furoate/vilanterol in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to May 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view, and the monthly briefing PDF. Sample rows shown below with the numbers obscured.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track fluticasone furoate/vilanterol like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Fluticasone furoate/vilanterol for you.